Cubic Zinc-Doped Iron Oxide Nanoparticles with Poly(Ethylene Glycol) or Sodium Citrate Surface Coatings for Tumor Imaging
Source abstract
Abstract
Magnetic resonance imaging (MRI) has been extensively studied over the past few decades, so developing strategies to enhance the T 2 contrast is of significant importance. Herein, we synthesized a series of cubic zinc-doped iron oxide nanoparticles (CZINs) with different dopant ratios by the thermal decomposition method. CZINs with a dopant ratio of 1:5 show the best magnetic performance and T 2 relaxivity among all CZINs. More importantly, we demonstrate that differentiated surface modifications lead to diverse in vivo behavior of CZINs, resulting in the distinct contrast efficiency for different types of tumor. Compared to sodium citrate (SC)-modified CZINs, polyethylene glycol (PEG)-modified CZINs show lower protein absorption, longer blood circulation time, and lower uptake amount in liver. These behavior differences lead PEG-modified CZINs to be potential candidates for assisting precise subcutaneous tumor diagnosis, while SC-modified CZINs are more suitable for achieving accurate liver metastases imaging. This research holds significant promise to develop potential T 2 contrast agents, which can be translated into clinical practice.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Iron oxide chemistry and applications · Characterization and Applications of Magnetic Nanoparticles
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology, Daping Hospital, Army Medical Center of PLA, Army Medical University, Chongqing 400042, China
College of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China
Department of Radiology, Strategic Support Force Medical Center, Beijing 100101, China
Chongqing Clinical Research Center for Imaging and Nuclear Medicine, Chongqing 400042, China
Funding
National Natural Science Foundation of China · Chongqing Clinical Research Centre of Imaging and Nuclear Medicine
References (40)
Show source-provided references
1. 10.1021/acs.chemrev.8b0036310.1021/acs.chemrev.8b00363 ↗
2. 10.1148/radiol.201919211310.1148/radiol.2019192113 ↗
3. 10.1148/radiol.23145410.1148/radiol.231454 ↗
4. 10.1039/D1TB02572D10.1039/D1TB02572D ↗
5. 10.7150/thno.6737510.7150/thno.67375 ↗
6. 10.1148/ryct.21032310.1148/ryct.210323 ↗
7. 10.1021/acsnano.3c0204110.1021/acsnano.3c02041 ↗
8. 10.1021/nl102623x10.1021/nl102623x ↗
9. 10.3390/ijms2107245510.3390/ijms21072455 ↗
10. 10.1002/adma.20180456710.1002/adma.201804567 ↗
11. 10.1021/acsami.8b1622610.1021/acsami.8b16226 ↗
12. 10.1016/j.actbio.2022.08.03310.1016/j.actbio.2022.08.033 ↗
13. 10.1038/ncomms326610.1038/ncomms3266 ↗
14. 10.1039/D1NR00338K10.1039/D1NR00338K ↗
15. 10.1038/nm146710.1038/nm1467 ↗
16. 10.3390/nano1005090710.3390/nano10050907 ↗
17. 10.3390/nano911160210.3390/nano9111602 ↗
18. 10.1016/j.jece.2019.10317910.1016/j.jece.2019.103179 ↗
19. 10.1002/exp.2023006110.1002/exp.20230061 ↗
20. 10.1016/j.cbi.2022.11017310.1016/j.cbi.2022.110173 ↗
21. 10.1016/j.apsadv.2021.10014510.1016/j.apsadv.2021.100145 ↗
22. 10.1021/acs.chemmater.9b0158210.1021/acs.chemmater.9b01582 ↗
23. 10.1021/acs.chemmater.0c0479410.1021/acs.chemmater.0c04794 ↗
24. 10.1002/smll.20220166910.1002/smll.202201669 ↗
25. 10.1021/acs.chemmater.7b0003510.1021/acs.chemmater.7b00035 ↗
26. 10.1021/acsabm.9b0124410.1021/acsabm.9b01244 ↗
27. 10.1007/s41061-020-00302-w10.1007/s41061-020-00302-w ↗
28. 10.1016/j.addr.2022.11439610.1016/j.addr.2022.114396 ↗
29. 10.1002/adhm.20220121410.1002/adhm.202201214 ↗
30. 10.1021/acsami.3c1394810.1021/acsami.3c13948 ↗
31. 10.1021/acsami.9b0795710.1021/acsami.9b07957 ↗
32. 10.1088/1361-6528/ac66ef10.1088/1361-6528/ac66ef ↗
33. 10.1021/acsbiomaterials.3c0123910.1021/acsbiomaterials.3c01239 ↗
34. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
35. 10.1021/acsami.2c1437510.1021/acsami.2c14375 ↗
36. 10.1002/smll.20220707710.1002/smll.202207077 ↗
37. 10.1016/j.ijpharm.2016.08.05810.1016/j.ijpharm.2016.08.058 ↗
38. 10.1038/nmat125110.1038/nmat1251 ↗
39. 10.1021/acs.chemmater.3c0135610.1021/acs.chemmater.3c01356 ↗
40. 10.1021/acsomega.3c0207910.1021/acsomega.3c02079 ↗